Pathogenesis of the antiphospholipid syndrome revisited: time to challenge the dogma

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 6, 2016, Pages 1117-1120

  Lackner, K J ^a   Muller Calleja N ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

anticardiolipin cofactor; antiphospholipid antibodies; antiphospholipid syndrome; beta2 glycoprotein I; venous thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; CARDIOLIPIN ANTIBODY; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BINDING AFFINITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; LIPID ANALYSIS; MOLECULAR PATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 84974710111     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13320     Document Type: Article

References (21)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.
2. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of the antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7: 330–9.
3. Brandt KJ, Kruithof EKO, de Moerloose P. Receptors involved in cell activation by antiphospholipid antibodies. Thromb Res 2013; 132: 408–13.
4. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368: 1033–44.
5. Du VX, Kelchtermans H, de Groot PG, de Laat B. From antibody to clinical phenotype, the black box of the antiphospholipid syndrome: pathogenic mechanisms of the antiphospholipid syndrome. Thromb Res 2013; 132: 319–26.
6. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990; 87: 4120–4.
7. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544–7.
8. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Suzuki T, Sumida T, Yasuda T, Koike T. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992; 148: 3885–91.
9. Pierangeli SS, Harris EN, Davis SA, DeLorenzo G. Beta 2-glycoprotein 1 (beta 2GP1) enhances cardiolipin binding activity but is not the antigen for antiphospholipid antibodies. Br J Haematol 1992; 82: 565–70.
10. Forastiero RR, Martinuzzo ME, Kordich LC, Carreras LO. Reactivity to beta2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Thromb Haemost 1996; 75: 717–20.
11. Müller-Calleja N, Köhler A, Siebald B, Canisius A, Orning C, Radsak M, Stein P, Mönnikes R, Lackner KJ. Cofactor-independent antiphospholipid antibodies activate the NLRP3-inflammasome via endosomal NADPH-oxidase: implications for the antiphospholipid syndrome. Thromb Haemost 2015; 113: 1071–83.
12. Levy RA, de Meis E, Pierangeli S. An adapted ELISA method for differentiating pathogenic from nonpathogenic aPL by a beta 2 glycoprotein I dependence anticardiolipin assay. Thromb Res 2004; 114: 573–7.
13. Arad A, Proulle V, Furie RA, Furie BC, Furie B. β2-glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood 2011; 117: 3453–9.
14. von Landenberg C, Lackner KJ, von Landenberg P, Lang B, Schmitz G. Isolation and characterization of two human monoclonal antiphospholipid IgG from patients with autoimmune disease. J Autoimmun 1999; 13: 215–223.
15. Prinz N, Clemens N, Strand D, Pütz I, Lorenz M, Daiber A, Stein P, Degreif A, Radsak M, Schild H, Bauer S, von Landenberg P, Lackner KJ. Antiphospholipid-antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells. Blood 2011; 118: 2322–32.
16. Pierangeli SS, Liu XW, Anderson G, Barker JH, Harris EN. Thrombogenic properties of murine anti-cardiolipin antibodies induced by b2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Circulation 1996; 94: 1746–51.
17. Pierangeli SS, Liu X, Espinola R, Olee T, Zhu M, Harris NE, Chen PP. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000; 84: 388–95.
18. Manukyan D, Müller-Calleja N, Jäckel S, Luchmann K, Mönnikes R, Kiouptsi K, Reinhardt C, Jurk K, Walter U, Lackner KJ. Cofactor independent human antiphospholipid antibodies induce venous thrombosis in mice. J Thromb Haemost 2016; 14: 1011–20.
19. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827–32.
20. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717–23.
21. Reynaud Q, Lega J-C, Mismetti P, Chapelle C, Wahl D, Cathébras P, Laporte S. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 2014; 13: 595–608.